ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid

Adjuvant endocrine therapy (AET) is the treatment of choice for early-stage estrogen receptor alpha (ERα)-positive breast cancer (BC). However, almost 40% of tamoxifen-treated cases display no response or a partial response to AET, thus increasing the need for new treatment options and strong predic...

Full description

Bibliographic Details
Main Authors: Aggeliki K. Meligova, Dimitra Siakouli, Sotiria Stasinopoulou, Despoina S. Xenopoulou, Maria Zoumpouli, Vassiliki Ganou, Eleni-Fani Gkotsi, Aristotelis Chatziioannou, Olga Papadodima, Eleftherios Pilalis, Michael N. Alexis, Dimitra J. Mitsiou
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
ERβ1
ERβ2
prognostic markers
tamoxifen
ICI182,780
Online Access:https://www.mdpi.com/1422-0067/24/4/3747

Internet

https://www.mdpi.com/1422-0067/24/4/3747

Similar Items